このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ステロイド抵抗性肺炎患者の治療におけるインフリキシマブおよび静脈内免疫グロブリン療法

2026年9月5日 更新者:ECOG-ACRIN Cancer Research Group

ステロイド抵抗性抗 PD-1/PD-L1 肺炎に対する免疫抑制の最適化

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.

調査の概要

状態

終了しました

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To assess pneumonitis response to additional immunosuppression (infliximab or intravenous immunoglobulin therapy [IVIG]) in patients with steroid-refractory pneumonitis at 28-days.

SECONDARY OBJECTIVES:

I. To assess functional parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

II. To assess radiologic parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

III. To assess patient-reported outcomes of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).

IV. To assess death after additional immunosuppression. V. To assess the rate of infections in the 28-day period after additional immunosuppression.

EXPLORATORY OBJECTIVES:

I. To examine lung tissue, bronchoalveolar lavage (BAL) and serial blood samples in patients who develop steroid-refractory pneumonitis.

II. To examine associations between BAL phenotypes and pneumonitis response, functional and radiologic parameters of pneumonitis.

III. To evaluate associations between pneumonitis and autoantibodies, T-cell expansion, and baseline cytokines in the blood.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive infliximab intravenously (IV) on day 1 followed by prednisone taper IV or orally (PO) for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.

ARM B: Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28, 42 and 56 days.

研究の種類

介入

入学 (実際)

1

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Michigan
      • Battle Creek、Michigan、アメリカ、49017
        • Bronson Battle Creek
      • Grand Rapids、Michigan、アメリカ、49503
        • Spectrum Health at Butterworth Campus
      • Grand Rapids、Michigan、アメリカ、49503
        • Mercy Health Saint Mary's
      • Kalamazoo、Michigan、アメリカ、49007
        • West Michigan Cancer Center
      • Muskegon、Michigan、アメリカ、49444
        • Mercy Health Mercy Campus
      • Niles、Michigan、アメリカ、49120
        • Lakeland Hospital Niles
      • Norton Shores、Michigan、アメリカ、49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City、Michigan、アメリカ、49677
        • Spectrum Health Reed City Hospital
      • Saint Joseph、Michigan、アメリカ、49085
        • Lakeland Medical Center Saint Joseph
      • Saint Joseph、Michigan、アメリカ、49085
        • Marie Yeager Cancer Center
      • Traverse City、Michigan、アメリカ、49684
        • Munson Medical Center
      • Wyoming、Michigan、アメリカ、49519
        • Metro Health Hospital
    • New York
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19111
        • Fox Chase Cancer Center
    • Virginia
      • Richmond、Virginia、アメリカ、23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond、Virginia、アメリカ、23298
        • Virginia Commonwealth University/Massey Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must be English-speaking and be able to provide informed consent

  • Patient must be willing and able to undergo arterial blood gas assessment as per the treating investigator. Patient must not have contraindication for arterial blood gas assessment

  • Women must not be pregnant or breast-feeding due to the potential risk to the fetus of infliximab or IVIG. All females of childbearing potential must have a blood test or urine test within 14 days prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method(s) of contraception or to abstain from sexual intercourse for a minimum of 56 days (the duration of their participation in the study)

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

  • Patient may have received any number of lines of prior systemic therapy

  • Patient may have any solid tumor or hematologic malignancy is eligible

  • Patient must have received treatment with an anti-PD-1/PD-L1 agent either alone or in combination with another anti-cancer agent, as their most recent therapy prior to development of pneumonitis

  • Patient must have steroid-refractory pneumonitis defined as:

    • Grade 2 pneumonitis that has not clinically improved by a Common Terminology Criteria for Adverse Events (CTCAE) grade in greater than 72 hours or maximum of 14 days or
    • Grade 3 or higher pneumonitis that has not clinically improved by a CTCAE grade in greater than 48 hours or maximum of 14 days with high dose corticosteroids (methylprednisolone or prednisone 1-4 mg/kg/equivalent) as their most recent treatment for pneumonitis, as determined by the treating investigator
  • Patient may have received anti-PD-1/PD-L1 therapy as standard-of-care or part of a clinical trial

  • Patient must have had pathogen-negative infectious diagnostic evaluation within 14 days prior to randomization, and at a minimum these should include: blood culture, urine culture, sputum culture, and viral panel: rapid flu, respiratory syncytial virus (RSV), herpes simplex virus (HSV). Empiric antibiotics for culture negative infections are not an exclusion for study entry

  • Patient must have had a pathogen-negative bronchoscopic assessment of BAL fluid within 14 days prior to randomization. A minimum assessment for pathogens on BAL must include: gram stain, fungal panel, viral panel

  • Patient must have a negative tuberculosis assessment (TB spot test, quantiferon gold or tuberculin skin test) within 14 days prior to randomization

  • Patient must have chest computed tomography (CT) scan without contrast performed =< 14 days before randomization. Patient must not have a contraindication for CT

Exclusion Criteria:

  • Patient must not have clinical evidence of cardiac dysfunction (as determined by the treating investigator) as an alternative diagnosis to steroid-refractory pneumonitis
  • Patient must not be receiving anti-PD-1/-PD-L1 agent in combination with any of the following anti-cancer agents: docetaxel, cyclophosphamide, gefitinib, erlotinib, osimertinib, crizotinib, bleomycin, afatinib
  • Patient must not be receiving concurrent radiation therapy to the chest
  • Patient must not be deemed to have radiation pneumonitis. Patients with a history of stable radiation pneumonitis not requiring corticosteroid therapy within the last 3 months prior to randomization will be allowed on study
  • Patient must not have pre-existing interstitial lung disease or pneumonitis requiring corticosteroid therapy from any other cause, as determined by the treating investigator
  • Patient must not have an absolute contraindication to IVIG or infliximab, including: clinical history of severe hypersensitivity reaction, selective IgA deficiency, active hepatitis B, active tuberculosis, active human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) where a study subject has a CD4 count of =< 200 at screening, or drug interaction

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm A (infliximab)

Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.

Given IV

他の名前:
  • レミケード

Given IV or PO

他の名前:
  • デルタゾン
  • オラソネ
  • メティコーテン
  • パナソル-S
  • 液体プレド

Given IV or PO

他の名前:
  • メチルプレドニゾロン (メドロール)
  • コハク酸メチルプレドニゾロンナトリウム (Solu-Medrol)
  • 酢酸メチルプレドニゾロン (Depo-Medrol)
実験的:Arm B (intravenous immunoglobulin therapy)

Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.

Given IV or PO

他の名前:
  • デルタゾン
  • オラソネ
  • メティコーテン
  • パナソル-S
  • 液体プレド

Given IV or PO

他の名前:
  • メチルプレドニゾロン (メドロール)
  • コハク酸メチルプレドニゾロンナトリウム (Solu-Medrol)
  • 酢酸メチルプレドニゾロン (Depo-Medrol)

Given IV

他の名前:
  • IVIG
  • 静脈内免疫グロブリン
  • ガンマグロブリン
  • ガンマグロブリン療法
  • 免疫グロブリン
  • 免疫グロブリン療法

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pneumonitis Response Rate
時間枠:At day 28

Pneumonitis response will be defined as an improvement in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) of >= 20% measured by PaO2 and recording of the FiO2 received by the patient at the time of the arterial blood gas assessment, on day 28 compared with day 1.

At day 28

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Patients With Radiologic Response for Steroid-refractory Pneumonitis
時間枠:At days 1, 14, and 28

Radiologic features of steroid-refractory pneumonitis will be assessed by percentage lung parenchyma involved, percentage of ground-glass opacity in lung parenchyma, and lung volume on computed tomography. The pneumonitis and lung volume will be graded "Definitely decreased", "Probably decreased", "No significant change", "Probably increased" and "Definitely increased". Response to study therapy will be defined by combining the categories "Definitely decreased" and "Probably decreased".

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Spirometry
時間枠:At days 1, 14, and 28

Functional features of pneumonitis will be assessed by spirometry (forced vital capacity, forced expiratory volume in one second). These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Diffusion Capacity
時間枠:At days 1, 14, and 28

Functional features of pneumonitis will be assessed by diffusion capacity of the lung. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Functional Parameters of Steroid-refractory Pneumonitis by Oxygen Saturation
時間枠:At days 1, 14, and 28

Functional features of pneumonitis will be assessed by oxygen saturation on room air at rest, collected as part of the vital signs. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms.

At days 1, 14, and 28
Number of Deaths Within 28 Days
時間枠:Up to 28 days

Death reported in the 28-day period will be tabulated by treatment arm, and classified as pneumonitis-related, immunosuppression related, disease-related or other.

Up to 28 days
Incidence of Adverse Events
時間枠:Up to 28 days

Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number and severity of treatment-related adverse events from infections in any organ system by the CTCAE reported in the 28-day period after additional immunosuppression.

Up to 28 days
Total Score of Functional Assessment of Cancer Therapy - Lung Version 4
時間枠:At days 1, 14, and 28

Patient-reported outcomes of steroid-refractory pneumonitis will be measured by questionnaires (Functional Assessment of Cancer Therapy - Lung version 4 [FACT-L]). FACT-L consists of 5 subscales and the total score is calculated by summing the scores of the 36 items. The score ranges between 0 and 136. The higher the score, the better the quality of life.

At days 1, 14, and 28

その他の成果指標

結果測定
メジャーの説明
時間枠
Distribution of Biomarkers in Patients Who Develop Steroid-refractory Pneumonitis
時間枠:Days 1, 14 and 28 after study treatment

Potential blood/serum biomarkers for pneumonitis will be assessed from serially collected blood/serum in accrued patients (on Days 1, 14 and 28 after study treatment) and controls, whose blood/serum will be obtained as part of a parallel tissue-collection protocol.

Days 1, 14 and 28 after study treatment
To Evaluate Associations Between Pneumonitis and Autoantibodies, T Cell Expansion, and Baseline Cytokines in the Blood
時間枠:On days 1, 14, and 28 post-treatment

To evaluate associations between pneumonitis and autoantibodies, T cell expansion, and baseline cytokines in the blood.

On days 1, 14, and 28 post-treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Jarushka Naidoo、ECOG-ACRIN Cancer Research Group

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月7日

一次修了 (実際)

2023年12月21日

研究の完了 (実際)

2026年5月26日

試験登録日

最初に提出

2020年6月9日

QC基準を満たした最初の提出物

2020年6月16日

最初の投稿 (実際)

2020年6月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月5日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • EAQ172
  • EAQ172 (その他の識別子:CTEP)
  • NCI-2018-02825 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • UG1CA189828 (米国 NIH グラント/契約)
  • EAQ172 (その他の識別子:ECOG-ACRIN Cancer Research Group)
  • EAQ172 (その他の識別子:DCP)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。